Position in ABBV
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$508,061
+$95,700 QoQ
Shares Held
2,019
+6.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.46%
of 13F equity value
Holder Rank
#3,135
of 4,153 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026PAX Financial Group, LLC holds $3,929,562 across 7 Drug Manufacturers - General names. ABBV ranks #4 (12.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
1,103 | $1,322,971 | |
| 2 | NVO |
Novo Nordisk A S
|
13,437 | $644,169 | |
| 3 | JNJ |
Johnson & Johnson
|
2,114 | $536,892 | |
| 4 | ABBV |
AbbVie Inc.
This page
|
2,019 | $508,061 | |
| 5 | AZN |
Astrazeneca PLC
|
2,504 | $474,808 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
1,794 | $226,653 | |
| 7 | MRK |
Merck & Co., Inc.
|
1,681 | $216,008 |
All Filings in ABBV
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $508,061 | 2,019 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $412,361 | 1,896 | Shares | Sole | 2026-04-27 | |
| 2025-12-31 | $510,675 | 2,235 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $571,903 | 2,470 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $440,847 | 2,375 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $572,199 | 2,731 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $380,100 | 2,139 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $372,842 | 1,888 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $274,260 | 1,599 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $216,699 | 1,190 | Shares | Sole | 2024-05-13 | |
| No filing history on record for this holder in this stock. | ||||||